SCHEMBL6842436

SCHEMBL6842436

CCOC(=O)c1cn(Cc2cccc3ccccc23)cc1C(=O)OCC

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC25B P30305 2/20 0.57
FNTA P49354 1/20 0.54
FNTB P49356 1/20 0.54
CDC25A P30304 1/20 0.53
CDC25C P30307 1/20 0.53
ALDH1A1 P00352 5/20 0.50
KMT2A Q03164 4/20 0.50
MAPT P10636 3/20 0.50
TDP1 Q9NUW8 2/20 0.50
LMNA P02545 2/20 0.50
HPGD P15428 2/20 0.50
TSHR P16473 1/20 0.49
KDM4E B2RXH2 5/20 0.47
GAA P10253 2/20 0.46
MEN1 O00255 2/20 0.46
NPSR1 Q6W5P4 1/20 0.46
GLA P06280 1/20 0.46
RAB9A P51151 3/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
NFKB1 P19838 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6165250 0.81 FNTA (0.51) CDC25BFNTAFNTBCDC25ACDC25C
SCHEMBL7105819 0.81 KDM4E (0.47) CDC25BFNTAFNTBCDC25ACDC25C
SCHEMBL27531649 0.80 NR4A1 (0.53) CDC25BKMT2AMAPTTDP1LMNA
SCHEMBL277672 0.78 CDC25B (0.82) CDC25BCDC25ACDC25CALDH1A1KMT2A
SCHEMBL6848160 0.77 MAPK8 (0.46) ALDH1A1KMT2AMAPTTDP1LMNA
SCHEMBL3606815 0.76 MAPT (0.46) CDC25BFNTAFNTBCDC25ACDC25C
SCHEMBL15729935 0.75 MAPT (0.53) CDC25BCDC25ACDC25CALDH1A1KMT2A
SCHEMBL8589767 0.74 CDC25B (0.70) CDC25BCDC25ACDC25CALDH1A1KMT2A
SCHEMBL3180834 0.74 SLC22A12 (0.47) CDC25BCDC25ACDC25CALDH1A1KMT2A
SCHEMBL5864678 0.73 GAA (0.59) CDC25BCDC25ACDC25CALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6770646-B2 PYRROLO-, THIENO-, FURANO-AND PYRAZOLO-(3,4-D)-PYRIDAZINONES; USED FOR TREATING REVERSIBLE OBSTRUCTIVE AIRWAYS DISEASE AND EFFECTING IMMUNOSUPPRESSION ASTRAZENECA AB (SE) 2004-08-03 US disclosed
EP-1036076-B1 NOVEL COMPOUNDS ASTRAZENECA UK LTD (GB) 2002-09-04 EP disclosed
US-20020099055-A1 Novel compounds ASTRAZENECA AB. 2002-07-25 US disclosed
US-6342601-B1 TREATING ALLOGRAFT REJECTION, RHEUMATOID ARTHRITIS ASTRAZENECA AB (SE) 2002-01-29 US disclosed
EP-1036076-A1 NOVEL COMPOUNDS AstraZeneca UK Limited (GB) 2000-09-20 EP disclosed
WO-1999029695-A1 NOVEL COMPOUNDS ASTRAZENECA UK LIMITED (GB) 1999-06-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020099055-A1 Novel compounds THPO, CYP4B1, CYP3A4 CDC25B 1460/4885FNTA 1148/4885FNTB 2444/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.